please prove me wrong, page-21

thanks J8!

it's always been an intruiging stock to research - initially the patent battles, and now the research across so many fronts.

the two papers are great, but there are other things that have happened of late that haven;t been priced:

- Alny InterfRx options must be up x10 from two weeks ago
since Alny announced they got siRNA to work at a therapuetic level last week. sp didn't see this.

- John Rossi with investor update in Nov advising one patient in the first generation trial now at 3 years modified T cell marking in the HIV trial. The patient has
6 x more modified cells in his system than they started him with!! It's only a safety trial - extrapolate that to
an efficious dose,using the improved second generation molecule and protocol (due to start now) and the patient's well on his way to a cure IMHO. sp didn't see that either.